Core Insights - The company, Green Bamboo Bio-B (02480.HK), announced positive immunogenicity and safety data for its core product LZ901 in a head-to-head comparison with the HZ/su vaccine (Shingrix®) in adults aged 50 and above [1] Group 1: Clinical Trial Results - A randomized, active-controlled, non-inferiority trial was conducted, enrolling 301 healthy adults aged 50 and above, with at least 291 receiving two doses of either LZ901 or HZ/su vaccine [1] - LZ901 demonstrated superior cellular immunogenicity and better safety profile compared to the HZ/su vaccine in the target demographic [1] Group 2: Product Development - LZ901 is a recombinant shingles vaccine developed by the company, aimed at preventing shingles and related complications, including postherpetic neuralgia, in adults aged 40 and above [1] - As of the announcement date, the biological product license application for LZ901 has been accepted by the National Medical Products Administration of China and is currently under review [1]
绿竹生物-B(02480.HK)：LZ901头对头比较研究的积极临床数据